Top

Published in:

01-09-2009 | Preclinical Study

Evaluation of a RT-PCR based routine screening tool for the detection of disseminated epithelial cells in the bone marrow of breast cancer patients

Authors: Sven Becker, Graziella Becker-Pergola, Malgorzata Banys, Natalia Krawczyk, Diethelm Wallwiener, Erich Solomayer, Christina Schuetz, Tanja Fehm

Published in: Breast Cancer Research and Treatment | Issue 2/2009

Abstract

Purpose Numerous studies have shown that the presence of clinically occult disseminated tumor cells (DTC’s) in the bone marrow (BM) of breast cancer patients is associated with an unfavourable clinical outcome. Immunocytochemistry (ICC) remains the gold standard for their detection. While assays based on RT-PCR are available, they have not been used for routine detection of DTC’s. Methods To assess the quality of the assay, we performed a direct comparison of DTC detection rates in a large cohort of 385 patients using both standardized ICC and real-time RT-PCR protocols. Correlation rates were assessed, and results were compared with clinical data. Results A significant correlation between ICC and RT-PCR was observed (P < 0.01). Positivity rates were similar (both 35%) and the results of both methods agreed in 73% of cases (280/385). Conclusions We describe a real-time RT-PCR based protocol for DTC-detection that has been specifically designed for routine clinical laboratory use. As such, RT-PCR has the potential to become an alternative testing method for BM evaluation in breast cancer patients.

Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ et al (2005) International expert consensus on the primary therapy of early breast cancer. Ann Oncol 6:1569–1583. doi:10.1093/annonc/mdi326 CrossRef

Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793–802. doi:10.1056/NEJMoa050434 PubMedCrossRef

Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR et al (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525–533. doi:10.1056/NEJM200002243420801 PubMedCrossRef

Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF et al (1996) Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 88:1652–1658. doi:10.1093/jnci/88.22.1652 PubMedCrossRef

Solomayer EF, Diel IJ, Salanti G, Hahn M, Gollan C, Schutz F et al (2001) Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients. Clin Cancer Res 7:4102–4108PubMed

Borgen E, Naume B, Nesland J, Kvalheim G, Beiske K, Fodstad O et al (1999) Standardization of the immunocytochemical detection of cancer cells in BM and Blood: I. Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1:377–388. doi:10.1080/0032472031000141283 CrossRef

Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C et al (2006) A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 107:885–892. doi:10.1002/cncr.22076 PubMedCrossRef

Benoy IH, Elst H, Van der Auwera I, Van Laere S, van Dam P, Van Marck E et al (2004) Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer. Br J Cancer 91:1813–1820. doi:10.1038/sj.bjc.6602189 PubMedCrossRef

Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS (1994) Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 12:475–482PubMed

10.

Reinholz MM, Nibbe A, Jonart LM, Kitzmann K, Suman VJ, Ingle JN et al (2005) Evaluation of a panel of tumor markers for molecular detection of circulating tumor cells in women with suspected breast cancer. Clin Cancer Res 11:3722–3732. doi:10.1158/1078-0432.CCR-04-1483 PubMedCrossRef

11.

Bosma AJ, Weigelt B, Lambrechts AC, Verhagen OJ, Pruntel R, Hart AA et al (2002) Detection of circulating breast tumor cells by differential expression of marker genes. Clin Cancer Res 8:1871–1877PubMed

12.

Gradilone A, Gazzaniga P, Silvestri I, Gandini O, Trasatti L, Lauro S et al (2003) Detection of CK19, CK20 and EGFR mRNAs in peripheral blood of carcinoma patients: correlation with clinical stage of disease. Oncol Rep 10:217–222PubMed

13.

Eaton MC, Hardingham JE, Kotasek D, Dobrovic A (1997) Immunobead RT-PCR: a sensitive method for detection of circulating tumor cells. Biotechniques 22:100–105PubMed

14.

Jamshidi K, Swaim WR (1971) Bone marrow biopsy with unaltered architecture: a new biopsy device. J Lab Clin Med 77:335–342PubMed

15.

Ruud P, Fodstad O, Hovig E (1999) Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase polymerase chain reaction assays used to detect micrometastatic tumor cells. Int J Cancer 80:119–125. doi:10.1002/(SICI)1097-0215(19990105)80:1<119::AID-IJC22>3.0.CO;2-XPubMedCrossRef

16.

Becker S, Becker-Pergola G, Fehm T, Wallwiener D, Solomayer EF (2004) Time is an important factor when processing samples for the detection of disseminated tumor cells in blood/bone marrow by reverse transcription-PCR. Clin Chem 50:785–786. doi:10.1373/clinchem.2003.025510 PubMedCrossRef

17.

Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland JM, Qvist H et al (2003) Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 21:3469–3478. doi:10.1200/JCO.2003.02.009 PubMedCrossRef

18.

Janni W, Rjosk D, Braun S (2000) Clinical relevance of occult metastatic cells in the bone marrow of patients with different stages of breast cancer. Clin Breast Cancer 1:217–225PubMedCrossRef

19.

Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A et al (2006) Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 24:3756–3762. doi:10.1200/JCO.2005.04.5948 PubMedCrossRef

20.

Gilbey A, Burnett D, Coleman R, Holen I (2004) The detection of circulating breast cancer cells. J Clin Pathol 57:903–911. doi:10.1136/jcp.2003.013755 PubMedCrossRef

21.

Ring A, Smith I, Dowsett M (2004) Circulating tumour cells in breast cancer. Lancet Oncol 5:79–88. doi:10.1016/S1470-2045(04)01381-6 PubMedCrossRef

22.

Silva JM, Dominguez G, Silva J, Garcia JM, Sanchez A, Rodriguez O et al (2001) Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin Cancer Res 7:2821–2825PubMed

23.

Kahn HJ, Yang LY, Blondal J, Lickley L, Holloway C, Hanna W et al (2000) RT-PCR amplification of CK19 mRNA in the blood of breast cancer patients: correlation with established prognostic parameters. Breast Cancer Res Treat 60:143–151. doi:10.1023/A:1006350913243 PubMedCrossRef

24.

Aerts J, Wynendaele W, Paridaens R, Christiaens MR, van den Bogaert W, van Oosterom AT et al (2001) A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood. Ann Oncol 12:39–46. doi:10.1023/A:1008317512253 PubMedCrossRef

25.

Berois N, Varangot M, Aizen B, Estrugo R, Zarantonelli L, Fernandez P et al (2000) Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer: comparison of CK19, MUC1 and CEA using RT-PCR. Eur J Cancer 36:717–723. doi:10.1016/S0959-8049(99)00338-X PubMedCrossRef

26.

Smith BM, Slade MJ, English J, Graham H, Luchtenborg M, Sinnett HD et al (2000) Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol 18:1432–1439PubMed

27.

Schroder CP, Ruiters MH, de Jong S, Tiebosch AT, Wesseling J, Veenstra R et al (2003) Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes. Int J Cancer 106:611–618. doi:10.1002/ijc.11295 PubMedCrossRef

28.

Schoenfeld A, Kruger KH, Gomm J, Sinnett HD, Gazet JC, Sacks N (1997) The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur J Cancer 33:854–861. doi:10.1016/S0959-8049(97)00014-2 PubMedCrossRef

29.

Naume B, Borgen E, Nesland JM, Beiske K, Gilen E, Renolen A et al (1998) Increased sensitivity for deteion of micrometastases in bone marrow/peripheral blood stem-cell products from bresast cancer patients by negative immunomagnetic separation. Int J Cancer 78:556–560. doi:10.1002/(SICI)1097-0215(19981123)78:5<556::AID-IJC5>3.0.CO;2-GPubMedCrossRef

30.

Benez A, Geiselhart A, Handgretinger R, Schiebel U, Fierlbeck G (1999) Detection of circulating melanoma cells by immunomagnetic cell sorting. J Clin Lab Anal 13:229–233. doi:10.1002/(SICI)1098-2825(1999)13:5<229::AID-JCLA7>3.0.CO;2-YPubMedCrossRef

31.

Stathopoulou A, Gizi A, Perraki M, Apostolaki S, Malamos N, Mavroudis D et al (2003) Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. Clin Cancer Res 9:5145–5151PubMed

32.

Ring AE, Zabaglo L, Ormerod MG, Smith IE, Dowsett M (2005) Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer 92:906–912. doi:10.1038/sj.bjc.6602418 PubMedCrossRef

33.

Slade MJ, Smith BM, Sinnett HD, Cross NC, Coombes RC (1999) Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer. J Clin Oncol 17:870–879PubMed

34.

Kruger W, Krzizanowski C, Holweg M, Stockschlader M, Kroger N, Jung R et al (1996) Reverse transcriptase/polymerase chain reaction detection of cytokeratin-19 mRNA in bone marrow and blood of breast cancer patients. J Cancer Res Clin Oncol 122:679–686. doi:10.1007/BF01209032 PubMedCrossRef

35.

36.

Pierga JY, Bonneton C, Magdelénat H, Vincent-Salomon A, Nos C, Boudou E et al (2005) Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients. Int J Cancer 114:291–298. doi:10.1002/ijc.20698 PubMedCrossRef

37.

de Cremoux P, Extra JM, Denis MG, Pierga JY, Bourstyn E, Nos C et al (2000) Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction. Clin Cancer Res 6:3117–3122PubMed

38.

Ferrucci PF, Rabascio C, Gigli F, Corsini C, Giordano G, Bertolini F et al (2007) New comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer. Int J Oncol 30:955–962PubMed

39.

Ko Y, Grunewald E, Totzke G, Klinz M, Fronhoffs S, Gouni-Berthold I et al (2000) High percentage of false-positive results of cytokeratin 19 RT-PCR in blood: a model for the analysis of illegitimate gene expression. Oncology 59:81–88. doi:10.1159/000012126 PubMedCrossRef

40.

Bostick PJ, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R et al (1998) Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 16:2632–2640PubMed

41.

Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpe S et al (2006) Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer 94:672–680PubMed

Title: Evaluation of a RT-PCR based routine screening tool for the detection of disseminated epithelial cells in the bone marrow of breast cancer patients
Authors: Sven Becker
Graziella Becker-Pergola
Malgorzata Banys
Natalia Krawczyk
Diethelm Wallwiener
Erich Solomayer
Christina Schuetz
Tanja Fehm
Publication date: 01-09-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0174-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China

Appropriateness of early breast cancer management in relation to patient and hospital characteristics: a population based study in Northern Italy

An educational video to increase clinical trials enrollment among breast cancer patients

Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis

Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells

Plasma carotenoids, tocopherols, retinol and breast cancer risk: results from the Shanghai Women Health Study (SWHS)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer